INTERNATIONAL PATENT: TAVARGENIX GMBH FILES APPLICATION FOR "COMBINATION THERAPY CONSISTING OF BENFO-OXYTHIAMINE AND/OR OXYTHIAMINE AND RADIONUCLIDE THERAPY"

GENEVA, June 16 -- TAVARGENIX GMBH (GrafenhauserstraBe 2664293 Darmstadt) filed a patent application (PCT/DE2024/100958) for "COMBINATION THERAPY CONSISTING OF BENFO-OXYTHIAMINE AND/OR OXYTHIAMINE AND RADIONUCLIDE THERAPY" on Nov 12, 2024. With publication no. WO/2025/119420, the details related to the patent application was published on Jun 12, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): COY, Johannes F. (Dr.-Euteneuer-Str. 1363512 Hainburg)

Abstract: The substances benfo-oxythiamine (B-OT) and/or oxythiamine (OT) are administered as active ingredient(s) in parallel with an ongoing r...